{
    "root": "27ad9395-c6d2-f500-ab18-07278b7c7b0e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Bortezomib",
    "value": "20250506",
    "ingredients": [
        {
            "name": "Bortezomib",
            "code": "69G8BD63PP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_52717"
        },
        {
            "name": "mannitol",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        }
    ],
    "indications": {
        "text": "bortezomib injection proteasome inhibitor indicated : treatment adult patients multiple myeloma ( 1.1 ) treatment adult patients mantle cell lymphoma ( 1.2 )",
        "doid_entities": [
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            },
            {
                "text": "mantle cell lymphoma (DOID:0050746)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050746"
            },
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "subcutaneous intravenous . route different reconstituted concentration . exercise caution calculating volume administered . ( 2.1 , 2.10 ) recommended starting dose bortezomib injection 1.3 mg/m 2 administered either 3 5 second bolus intravenous injection subcutaneous injection . ( 2.2 , 2.4 , 2.6 ) retreatment multiple myeloma : may retreat starting last tolerated dose . ( 2.6 ) hepatic impairment : lower starting dose patients moderate severe hepatic impairment . ( 2.8 ) dose must individualized prevent overdose . ( 2.10 )",
        "doid_entities": [
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "bortezomib injection supplied individually cartoned 10 ml vials containing 3.5 mg bortezomib white off-white cake powder . ndc 72603-270-01 3.5 mg single-dose vial unopened vials may stored 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . retain original package protect light . follow guidelines handling disposal hazardous drugs , including gloves protective clothing prevent skin contact1 .",
    "adverseReactions": "bortezomib injection contraindicated patients hypersensitivity ( including local ) bortezomib , boron , mannitol . included anaphylactic [ seeadverse ( 6.1 ) ] . bortezomib injection contraindicated intrathecal . fatal events occurred intrathecal bortezomib injection .",
    "indications_original": "Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 )",
    "contraindications_original": "For subcutaneous or intravenous use only. Each route of administration has a different reconstituted concentration. Exercise caution when calculating the volume to be administered. ( 2.1 , 2.10 ) The recommended starting dose of bortezomib for injection is 1.3 mg/m 2 administered either as a 3 to 5 second bolus intravenous injection or subcutaneous injection. ( 2.2 , 2.4 , 2.6 ) Retreatment for Multiple Myeloma: May retreat starting at the last tolerated dose. ( 2.6 ) Hepatic Impairment: Use a lower starting dose for patients with moderate or severe hepatic impairment. ( 2.8 ) Dose must be individualized to prevent overdose. ( 2.10 )",
    "warningsAndPrecautions_original": "Bortezomib for Injection is supplied as individually cartoned 10 mL vials containing 3.5 mg of bortezomib as a white to off-white cake or powder. \n                  NDC 72603-270-01\n                  3.5 mg single-dose vial \n                  Unopened vials may be stored at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [see USP Controlled Room Temperature]. Retain in original package to protect from light. \n                  Follow guidelines for handling and disposal for hazardous drugs, including the use of gloves and other protective clothing to prevent skin contact1.",
    "adverseReactions_original": "Bortezomib for injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [seeAdverse Reactions (6.1)]. \n                  Bortezomib for injection is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of bortezomib for injection.",
    "drug": [
        {
            "name": "Bortezomib",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_52717"
        }
    ]
}